New Zealand markets closed
  • NZX 50

    +37.31 (+0.33%)

    +0.0045 (+0.74%)

    +0.0042 (+0.74%)

    -12.60 (-0.17%)
  • ASX 200

    -14.10 (-0.20%)
  • OIL

    -1.64 (-2.16%)
  • GOLD

    +34.00 (+1.65%)

    +27.62 (+0.17%)
  • FTSE

    +75.60 (+1.01%)
  • Dow Jones

    +253.99 (+0.71%)
  • DAX

    +182.09 (+1.12%)
  • Hang Seng

    -212.58 (-1.25%)
  • NIKKEI 225

    -55.38 (-0.17%)

    -0.1370 (-0.15%)

TOMI Environmental Receives Order From National Institutes of Health (NIH); TOMI Products Now Deployed in Over 20 NIH Facilities Across 11 Divisions

TOMI Environmental Solutions, Inc.
TOMI Environmental Solutions, Inc.

FREDERICK, Md., Oct. 20, 2022 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announced that the U.S. Department of Health and Human Services (HHS), the largest biomedical research agency in the world, has purchased SteraMist disinfection systems for its Africa-based Biosafety Level 3 Laboratory (BSL-3) laboratory.

In 2016, NIH began using SteraMist to support the research of cutting-edge medical knowledge and development of revolutionary healthcare innovation – just one year after TOMI was awarded our EPA registration as a hospital-healthcare disinfectant. This purchase order reflects their continued implementation of SteraMist iHP technology within decontamination protocols to improve sterility and facility productivity.

This latest purchase is for two (2) SteraPak systems and two (2) Select Surface Units to support the disinfection requirements for an Africa-based Biosafety Laboratory, expanding NIH laboratory use of SteraMist to the international biosafety marketplace.

In total, NIH has deployed approximately thirty (30) SteraMist machines across eleven (11) divisions, including National Institute of Allergy & Infectious Diseases (NIAID), National Institute of Environmental Health Sciences (NIEHS), National Institute of Dental and Craniofacial Research (NIDCR), National Cancer Institute (NCI), Vaccine Research Center (VRC), and Rocky Mountain Laboratories (RML).

To assist in our mission to maintain controlled research environments, SteraMist’s low percentage (7.8%) of hydrogen peroxide protects uniquely customized facilities and valuable equipment from corrosion, minimizing overhead by avoiding the need to replace damaged surfaces and equipment. Additionally, SteraMist excels in the creation and management of controlled, decontaminated spaces.

Elissa J. (E.J.) Shane, COO of TOMI, states, “SteraMist is used throughout many government agencies, and we take pride in supporting customers like NIH. TOMI will continue to develop additional uses for SteraMist to promote NIH’s mission and we look forward to continuing to service their needs for many years to come.”

TOMI™ Environmental Solutions, Inc.: Innovating for a safer world®  

TOMI™ Environmental Solutions, Inc. (NASDAQ: TOMZ ) is a global decontamination and infection prevention company, providing environmental solutions for disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology ® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage hydrogen peroxide as its only active ingredient and uses patented ionized Hydrogen Peroxide (iHP™) technology in all SteraMist systems to create superior disinfection. TOMI products are designed to service a broad spectrum of use sites, including, but not limited to, hospitals and medical facilities, biosafety labs, pharmaceutical facilities, commercial and office buildings, schools, restaurants, meat and produce processing facilities, and police and fire departments.

For additional information, please visit or contact us at

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements relating to TOMI’s ability to develop products for NIH and government use. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, the impact of COVID-19 pandemic on our business and customers; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law.


John Nesbett/Jennifer Belodeau

IMS Investor Relations